The ACS’s mission-driven venture capital fund
Investing in for-profit companies developing novel cancer-focused treatments
Fighting for a world without cancer
Become a Donor
Our vision is to defeat cancer and advance health equity for ALL communities through patient-centric social innovation and intentional, mission-aligned impact investing.
BrightEdge exists to accelerate the American Cancer Society's goal to reduce cancer mortality, end pain and suffering, and advance health equity
Investing for science, social impact, and sustainability
BrightEdge invests invests in entrepreneurial early-stage companies developing cutting-edge cancer-focused therapeutics, diagnostics, devices, and technologies to bring innovative solutions to market.
Fighting for a World Without Cancer
BrightEdge is led by a world-class team of investors, operators, and entrepreneurs to accelerate the commercialization of the breadth of solutions needed to target cancer from all perspectives.
Third Rock Ventures Teams Up With American Cancer Society’s Venture Fund
The biotech venture firm will bring the society’s BrightEdge venture arm into cancer startup deals
FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)
American Cancer Society’s Impact Venture Capital Arm Secures $1 Million in New Contributions
Lyda Hill Philanthropies and Resonance Philanthropies Join Exclusive ACS BrightEdge Founders Circle
See All News